When you think of the pharmaceutical space, a few names consistently rise to the top — Pfizer, Johnson & Johnson, Eli Lilly. But sitting just as quietly powerful is Merck & Co. (MRK), a company with one of the most enviable product portfolios in healthcare and a balance sheet that makes it a long-term candidate for dividend-focused investors.
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.